China rejects patent on hepatitis C drug sofosbuvirBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h3429 (Published 23 June 2015) Cite this as: BMJ 2015;350:h3429
- Zosia Kmietowicz
- 1The BMJ
The Chinese patent office has rejected a patent application for the blockbuster hepatitis C treatment sofosbuvir, increasing the possibility of a generic version of the drug to become available in China.
The decision comes after a challenge by the Initiative for Medicines, Access and Knowledge (I-MAK), a US based group that campaigns for better access to affordable drugs. The group claimed that Gilead Sciences, the US biotechnology company that makes sofosbuvir, which recorded sales of more than $10bn in 2014, was seeking “illegitimate patents” for sofosbuvir and “blocking millions …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.